Once-Daily Plazomicin for Complicated Urinary Tract Infections

Treatment options for antimicrobial-resistant, gram-negative pathogens are limited. Plazomicin is an aminoglycoside antimicrobial agent that is resistant to aminoglycoside-modifying enzymes. In this trial involving 609 patients with complicated urinary tract infections, plazomicin was noninferior to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-02, Vol.380 (8), p.729-740
Hauptverfasser:	Wagenlehner, Florian M.E, Cloutier, Daniel J, Komirenko, Allison S, Cebrik, Deborah S, Krause, Kevin M, Keepers, Tiffany R, Connolly, Lynn E, Miller, Loren G, Friedland, Ian, Dwyer, Jamie P
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Administration, Oral Adult Aged Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Antibiotics Bacterial infections Bactericidal activity Body weight CRE bacteria Creatinine Drug Administration Schedule Drug Resistance, Multiple, Bacterial Enterobacteriaceae Enterobacteriaceae - drug effects Enterobacteriaceae Infections - drug therapy Enzymes Female Hospital costs Humans Intravenous administration Intravenous therapy Male Meropenem Meropenem - administration & dosage Meropenem - adverse effects Microbial Sensitivity Tests Middle Aged Multidrug resistance Patient Acuity Patients Pyelonephritis R&D Research & development Sisomicin - administration & dosage Sisomicin - adverse effects Sisomicin - analogs & derivatives Urinary tract Urinary tract diseases Urinary tract infections Urinary Tract Infections - drug therapy Urinary Tract Infections - microbiology Urogenital system Urology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Treatment options for antimicrobial-resistant, gram-negative pathogens are limited. Plazomicin is an aminoglycoside antimicrobial agent that is resistant to aminoglycoside-modifying enzymes. In this trial involving 609 patients with complicated urinary tract infections, plazomicin was noninferior to meropenem.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1801467